FE 204205

FE 204205 is a small molecule drug developed by Ferring Pharmaceuticals as a partial agonist of the vasopressin 1a receptor (AVPR1A). Its primary mechanism of action involves stimulating the vasopressin 1a receptor, which plays a role in vascular tone and fluid regulation. FE 204205 was investigated for the treatment of refractory ascites and portal hypertension, particularly in patients with cirrhotic portal hypertension. Clinical development included at least one phase 1 trial to assess safety, tolerability, pharmacodynamics, and pharmacokinetics after intravenous administration in this patient population. The development program has been discontinued[1][2][3].